860549P

C24:1 Glucosyl(β) Ceramide (d18:1/24:1(15Z))

Avanti Research^™ - A Croda Brand 860549P, powder

• Sinónimos: D-glucosyl-β-1,1′-N-nervonoyl-D-erythro-sphingosine
• Fórmula empírica (notación de Hill): C₄₈H₉₁NO₈
• Número de CAS: 887907-50-8
• Peso molecular: 810.24
• Código UNSPSC: 12352211
• NACRES: NA.25

Propiedades

• Formulario: powder
• envase: pkg of 1 × 5 mg (860549P-5mg)
• fabricante / nombre comercial: Avanti Research^™ - A Croda Brand 860549P
• tipo de lípido: sphingolipids
• Condiciones de envío: dry ice
• temp. de almacenamiento: −20°C
• cadena SMILES: [H][C@](/C=C/CCCCCCCCCCCCC)(O)[C@@]([H])(NC(CCCCCCCCCCCCC/C=C\CCCCCCCC)=O)CO[C@H](O1)[C@H](O)[C@@H](O)[C@@H]([C@H]1CO)O

Descripción

Descripción general

β-Glucosylceramides or glucocerebrosides (GlcCers) are synthesized from the glycosphingolipids by β-GlcCer synthase. They are synthesized in Golgi and endoplasmic reticulum and localized in the cytosolic side of cell membrane. GlcCers are omnipresent.

Aplicación

C24:1 Glucosyl(β) Ceramide (d18:1/24:1(15Z)) may be used:

• as a standard hexosylceramide for hydrophilic interaction chromatography-based liquid chromatography mass spectroscopy
• to test its nuclear factor of activated T-cells (NFAT) activation
• in human natural killer T (NKT) cell potency assays

Acciones bioquímicas o fisiológicas

β-Glucosylceramides (β-GlcCer) levels are elevated inlevels in Gaucher′s disease, due to the deficiency of β-glucosidase. β-GlcCer participates in the inflammatory and acquired immune responses by binding mincle on myeloid cells and has immunostimulatory activity.

Envase

5 mL Amber Glass Screw Cap Vial (860549P-5mg)

Información legal

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Información de seguridad

• Código de clase de almacenamiento: 11 - Combustible Solids